Trade Summary

4 days ago, Doyle Janeen Noel, serving as Chief Corp. & Bus. Dev. Ofcr at Janux Therapeutics, Inc. (JANX), sold 4,059 shares at $14.03 per share, for a total transaction value of $56,943.71. Following this transaction, Doyle Janeen Noel now holds 75,941 shares of JANX.

This sale represents a 5.07% decrease in Doyle Janeen Noel's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, June 2, 2026 and publicly disclosed via SEC Form 4 filing on Friday, June 5, 2026 (accepted Jun 4, 8:00 PM ET), 3 days after the trade was made.

Janux Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.